Bortezomib Completed Phase 2 Trials for Stage II Adult Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Adult Lymphocyte Depletion Hodgkin Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage I Adult Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Childhood Lymphocyte Predominant Hodgkin Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00381940Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
NCT00082966Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma